| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Rivaroxaban EP Impurity I has no therapeutic target; it is a pharmaceutical impurity. Rivaroxaban, the parent drug, is a highly potent, selective, direct Factor Xa inhibitor that blocks the conversion of prothrombin to thrombin, thereby inhibiting blood coagulation. This impurity is a byproduct formed during the synthesis of Rivaroxaban and is used solely as a reference standard for analytical purposes to ensure the purity and safety of Rivaroxaban drug products.
|
|---|---|
| ln Vitro |
The compound is not a drug and has no direct in vitro biological activity. It is used as an analytical reference standard for the determination of impurities in Rivaroxaban drug substance and finished products by high-performance liquid chromatography (HPLC). It is not tested in standard enzyme inhibition or cell viability assays for drug discovery.
|
| ln Vivo |
Not applicable. Rivaroxaban EP Impurity I is not administered in vivo. It is a pharmaceutical impurity and is used as an analytical reference standard. No in vivo therapeutic activity is reported. It is not intended for therapeutic use. It is used to ensure the quality of Rivaroxaban during manufacturing.
|
| Enzyme Assay |
Not applicable. The compound is a reference standard, not a standard enzyme inhibitor. Its purity (>95%) is assessed by HPLC. The structure is confirmed by ¹H NMR, ¹3C NMR, and mass spectrometry (ESI-MS, expected [M+H]+ m/z 599). Physicochemical properties: MW 598.48, white to off-white powder, soluble in DMSO and methanol. No biological assays are applicable.
|
| Cell Assay |
Not applicable. Rivaroxaban EP Impurity I is not used in standard cell-based assays for drug discovery. For toxicity screening, HepG2 or HEK293 cells are seeded in 96-well plates (1×10⁴ cells/well) and treated with the compound (1-1000 uM) for 24-72 h. Cell viability is measured by MTT assay. The CC₅0 is expected to be >100 uM, indicating moderate to low cytotoxicity. The compound is an impurity standard, not a test agent for pharmacological studies.
|
| Animal Protocol |
No in vivo animal protocol for Rivaroxaban EP Impurity I exists, as it is an impurity standard, not a drug candidate. For acute toxicity testing, female Sprague-Dawley rats (n=3-5 per dose) are administered a single oral dose of the compound in 0.5% methylcellulose at 500, 1000, 2000 mg/kg and observed for 14 days for mortality and clinical signs. The LD₅0 is expected to be >2000 mg/kg (low acute toxicity). This protocol is not typically performed for impurity standards.
|
| ADME/Pharmacokinetics |
No PK data for Rivaroxaban EP Impurity I is available, as it is an impurity and not a drug. It is not intended for systemic administration. For research use, it is stored at 2-8degC in a tightly sealed container, protected from light and moisture.
|
| Toxicity/Toxicokinetics |
For Rivaroxaban EP Impurity I, hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). Signal word: Warning. Precautionary statements: P261 (Avoid breathing dust/fume/gas/mist/vapors/spray), P280 (Wear protective gloves/protective clothing/eye protection/face protection), P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes). Storage: at 2-8degC, sealed, protect from light.
|
| References | |
| Additional Infomation |
Rivaroxaban EP Impurity I (CAS# 1151893-81-0) is a research-grade pharmaceutical impurity standard for the anticoagulant drug Rivaroxaban. It is not an FDA-approved drug. It is used for quality control (QC), analytical method development (AMV), and regulatory compliance in the production of Rivaroxaban. For research and quality control use only, not for diagnostic or therapeutic applications.
|
| Molecular Formula |
C24H21CL2N3O7S2
|
|---|---|
| Molecular Weight |
598.48
|
| Exact Mass |
597.02
|
| CAS # |
1151893-81-0
|
| PubChem CID |
57572379
|
| Appearance |
Typically exists as solids at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
843.9±65.0 °C at 760 mmHg
|
| Flash Point |
464.2±34.3 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.667
|
| LogP |
3.47
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
38
|
| Complexity |
880
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
ClC1=CC=C(C(N(CCOCC(=O)O)C2C=CC(=CC=2)N2C(=O)O[C@@H](CNC(C3=CC=C(S3)Cl)=O)C2)=O)S1
|
| InChi Key |
XEOFNNZMYBBFPT-INIZCTEOSA-N
|
| InChi Code |
InChI=1S/C24H21Cl2N3O7S2/c25-19-7-5-17(37-19)22(32)27-11-16-12-29(24(34)36-16)15-3-1-14(2-4-15)28(9-10-35-13-21(30)31)23(33)18-6-8-20(26)38-18/h1-8,16H,9-13H2,(H,27,32)(H,30,31)/t16-/m0/s1
|
| Chemical Name |
2-[2-[N-(5-chlorothiophene-2-carbonyl)-4-[(5S)-5-[[(5-chlorothiophene-2-carbonyl)amino]methyl]-2-oxo-1,3-oxazolidin-3-yl]anilino]ethoxy]acetic acid
|
| Synonyms |
Rivaroxaban Impurity I
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 125 mg/mL (~208.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6709 mL | 8.3545 mL | 16.7090 mL | |
| 5 mM | 0.3342 mL | 1.6709 mL | 3.3418 mL | |
| 10 mM | 0.1671 mL | 0.8354 mL | 1.6709 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
